Clinical dynamics and tolerability of Flexonorm® in dogs with pain syndrome of various origins

Rationale. Inadequate pain management in dogs following acute trauma, orthopedic and abdominal surgeries, as well as in chronic musculoskeletal disorders, limits physical activity and impairs quality of life. Furthermore, the administration of NSAIDs necessitates careful monitoring for potential adverse reactions. Objective. To describe the clinical dynamics and tolerability of Flexonorm® (robenacoxib) in dogs with postoperative and chronic pain syndromes within the setting of routine veterinary practice. Methods. From May to August 2026, an open-label, uncontrolled, post-marketing clinical study was conducted, involving 30 dogs of various breeds, ages, and body weights. The drug was administered orally as the sole analgesic. Owners completed a daily six-domain diary (0–2 points each, total score 0–12), while tolerability was assessed through clinical observations, laboratory tests, and ultrasonography. Results. Improvement in the condition was observed in 23 animals (76.7%), with the most pronounced dynamics noted in animal mobility and activity. The total functional score of the animals' condition in the logs increased from 10.0 [7.0; 11.0] to 12.0 [12.0; 12.0] points (p <0.001), indicating an improvement in the animals' health status. Evaluation of the complete blood count and biochemical blood analysis results in dogs before and after the Flexonorm® treatment course demonstrated good tolerability of the drug. According to follow-up ultrasound diagnostics, the condition of the dogs' internal organs remained within the clinical norm after the administration of Flexonorm®. Gastrointestinal adverse events were recorded in 3 dogs (10.0%); in one case, the drug was discontinued. No signs of toxic damage to internal organs were detected. Conclusion. The use of Flexonorm® as analgesic monotherapy was associated with an improvement in the functional status of the majority of dogs, with satisfactory tolerability.